KRYS

Krystal Biotech, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website krystalbio.com
Employees(FY) 210
ISIN US5011471027

Performance

-4.94%

-7.32%

-10.65%

-4.72%

+32.86%

YTD

+45.94%

Profile

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of KRYS 2024-12-20

The stock's indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, a neutral Oscillators Score of 50 suggesting indecision, and a Technical Score of 30 reinforcing the bearish outlook. This combination signals caution for potential investors as the stock appears to be under pressure.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of KRYS

Stock Rank

Recent News & Updates

2024-12-19 11:08
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707(Zacks)
2024-12-18 09:23
Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity(MT Newswires)
2024-12-18 08:00
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer(GlobeNewswire)
2024-12-17 19:00
KRYS: Lowering target price to $177.00(Argus Research)
2024-12-17 19:00
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer(Globenewswire)
2024-12-16 04:02
Krystal Biotech Insider Sold Shares Worth $8,240,023, According to a Recent SEC Filing(MT Newswires)
2024-12-13 11:08
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408(Zacks)
2024-12-12 19:20
Krystal Biotech announces initial update for KB408, KB407(Yahoo Finance)
2024-12-12 11:30
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?(Zacks)
2024-12-12 08:00
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels(GlobeNewswire)
2024-12-11 19:00
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels(Globenewswire)
2024-12-10 19:00
KRYS: What does Argus have to say about KRYS?(Argus Research)
2024-12-09 16:15
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa(GlobeNewswire)
2024-12-09 03:15
Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa(Globenewswire)
2024-12-05 11:30
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?(Zacks)
2024-12-04 11:30
Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?(Zacks)
2024-12-03 19:00
KRYS: Lowering target price to $195.00(Argus Research)
2024-11-29 09:50
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick(Zacks)
2024-11-27 07:00
Krystal Biotech to Present at Upcoming Investor Conferences(GlobeNewswire)
2024-11-26 19:00
KRYS: Raising target price to $206.00(Argus Research)
2024-11-26 18:00
Krystal Biotech to Present at Upcoming Investor Conferences(Globenewswire)
2024-11-12 19:00
KRYS: Raising target price to $197.00(Argus Research)
2024-11-12 13:02
High Growth Tech Stocks Featuring Three Prominent US Companies(Simply Wall St.)
2024-11-12 07:00
Krystal Biotech to Present at Stifel 2024 Healthcare Conference(GlobeNewswire)
2024-11-11 18:00
Krystal Biotech to Present at Stifel 2024 Healthcare Conference(Globenewswire)
2024-11-11 06:06
US Exchange Highlights 3 Growth Stocks With Strong Insider Ownership(Simply Wall St.)
2024-11-07 08:04
Krystal Biotech, Inc. (NASDAQ:KRYS) Just Released Its Third-Quarter Earnings: Here's What Analysts Think(Simply Wall St.)
2024-11-06 07:00
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference(GlobeNewswire)
2024-11-05 19:00
KRYS: Lowering target price to $183.00(Argus Research)
2024-11-05 18:00
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference(Globenewswire)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.